Zyrovazet 10/10 Mg 30 Tablets

Zyrovazet 10/10 Mg 30 Tablets

Description:

Zyrovazet 10/10 mg is a prescription oral lipid-lowering medicine that combines ezetimibe and rosuvastatin in a single film-coated tablet. It is used as part of a comprehensive strategy to manage high cholesterol and dyslipidemia, alongside a cholesterol-lowering diet and lifestyle changes. By targeting both intestinal cholesterol absorption and hepatic cholesterol synthesis, Zyrovazet helps reduce elevated low-density lipoprotein cholesterol (ldl-c), total cholesterol, and other atherogenic lipids, supporting cardiovascular risk reduction in appropriate patients under medical supervision.

Indications:

• Treatment of primary hypercholesterolemia (including heterozygous familial and non-familial) as an adjunct to diet when combination therapy with ezetimibe and rosuvastatin is appropriate.
• Management of mixed dyslipidemia in patients who require additional ldl-c reduction despite diet and other non-pharmacological measures.
• Adjunct to diet in patients with homozygous familial hypercholesterolemia, in combination with other lipid-lowering treatments (such as ldl apheresis) or when such treatments are not available or not appropriate.
• May be used in patients not adequately controlled on rosuvastatin or ezetimibe alone and for whom a fixed-dose combination is clinically suitable, as determined by the treating physician.
• Helps reduce elevated total cholesterol, ldl-c, non-hdl-c, and apolipoprotein b, which are associated with increased cardiovascular risk.

Active Ingredients / Key Components:

• Ezetimibe – 10 mg per film-coated tablet (cholesterol absorption inhibitor; 2-azetidinone derivative that selectively inhibits intestinal absorption of cholesterol and related phytosterols).
• Rosuvastatin (as rosuvastatin calcium or equivalent salt) – 10 mg per film-coated tablet (hmg-coa reductase inhibitor “statin” that reduces hepatic cholesterol synthesis and increases hepatic uptake of ldl-c).
• Other excipients: Full excipient list and their concentrations , please check the product leaflet or the manufacturer’s official website. Refer to the official package leaflet for complete inactive ingredient details.

Dosage & Administration / How to Use:

• Use only as prescribed by a physician experienced in the management of hyperlipidemia.
• Typical adult dose: 1 tablet of Zyrovazet 10/10 mg once daily, or as directed by your doctor, based on individual lipid levels, treatment goals, and response.
• Administration: Swallow the tablet whole with a glass of water. Do not crush or chew the film-coated tablet.
• Timing: Can be taken with or without food, preferably at the same time each day to support adherence.
• Baseline and ongoing monitoring: Lipid profile, liver function tests, and creatine kinase (ck) may be monitored periodically as recommended by your doctor.
• Missed dose: If you miss a dose, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose to make up for a missed tablet.
• Duration of use: Long-term therapy is often required to maintain lipid control. Do not stop treatment without consulting your healthcare provider.
• Concomitant therapy: If taken with bile acid sequestrants (e.g., cholestyramine), Zyrovazet should generally be taken at least 2 hours before or 4 hours after the sequestrant, as advised by your doctor.

Clinical Benefits:

• Provides dual mechanism lipid control by inhibiting intestinal cholesterol absorption (ezetimibe) and hepatic cholesterol synthesis (rosuvastatin).
• Effectively lowers ldl-cholesterol, total cholesterol, and non-hdl-cholesterol, supporting reduction of atherosclerotic cardiovascular risk when used as part of a comprehensive risk management plan.
• May improve other lipid parameters such as triglycerides and apolipoprotein b, and can help increase high-density lipoprotein cholesterol (hdl-c) in many patients.
• Convenient fixed-dose combination in a single daily tablet, which can enhance treatment adherence compared with taking separate ezetimibe and statin tablets.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to ezetimibe, rosuvastatin, or any component of the formulation.
• Contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases.
• Contraindicated during pregnancy and breastfeeding, as statins may harm the fetus or nursing infant. Women of childbearing potential should use effective contraception.
• Use with caution in patients with a history of liver impairment, heavy alcohol use, renal impairment, hypothyroidism, or personal/family history of hereditary muscle disorders.
• Risk of myopathy and rhabdomyolysis: Inform your doctor immediately if you experience unexplained muscle pain, tenderness, weakness, or cramps, especially if accompanied by malaise or fever.
• Concomitant use with certain medicines (e.g., cyclosporine, some protease inhibitors, certain fibrates, niacin, or other lipid-lowering drugs) may increase the risk of muscle or liver side effects; dose adjustments or alternative therapies may be required.
• Periodic liver function tests and, when indicated, creatine kinase measurements are recommended, particularly at therapy initiation or dose escalation.
• Consult your doctor before use if pregnant, nursing, planning pregnancy, taking other medications, or if you have medical conditions such as liver disease, kidney disease, thyroid disorders, diabetes, or a history of muscle problems.
• Not intended for use in children unless specifically prescribed by a specialist; pediatric dosing and safety depend on age and indication.
• Keep out of reach of children.

Side Effects:

• Common side effects may include headache, dizziness, abdominal pain, nausea, constipation, diarrhea, flatulence, fatigue, or muscle aches (myalgia).
• Less common but clinically important side effects can include elevated liver enzymes, increased creatine kinase, muscle inflammation (myositis), or severe muscle breakdown (rhabdomyolysis) which may lead to kidney damage.
• Other possible reactions: rash, pruritus, allergic reactions, joint pain, or changes in blood sugar levels in predisposed individuals.
• Seek immediate medical attention if you develop severe muscle pain or weakness, dark-colored urine, jaundice (yellowing of skin or eyes), severe abdominal pain, difficulty breathing, facial or tongue swelling, or any signs of a serious allergic reaction.
• This is not a complete list of side effects. Always review the official patient leaflet and consult your healthcare provider for personalized medical advice.

Storage Instructions:

Store in a cool, dry place away from direct sunlight and moisture. Keep the blister pack in the outer carton to protect from light. Do not store above the temperature specified on the package (exact temperature range is not available in the provided information; refer to the product box). Keep container tightly closed and out of reach of children. Do not use after the expiry date printed on the pack.

Specifications:

• Product type: Prescription lipid-lowering medicine (fixed-dose combination of ezetimibe and rosuvastatin).
• Strength: 10 mg ezetimibe + 10 mg rosuvastatin per film-coated tablet.
• Form: Film-coated tablet for oral use.
• Pack size: 30 tablets per pack.
• Intended users: Adults and suitable adolescents as determined by a physician for the treatment of hypercholesterolemia and dyslipidemia.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.